FARMINGTON, Conn., March 13, 2013 /PRNewswire-iReach/ -- Tools for engineering the next generation of antibodies and biologics will need to address the current challenges facing the industry. These include tapping into innovative ideas for developing antibodies against intracellular and membrane targets, engineering bispecific constructs, and designing antibodies for infectious disease and CNS applications. The versatility of phage and yeast display, coupled with vast improvements in antibody engineering and production, are expanding the realm of possibilities for creating therapeutic entities and improving their success rate.
15th Annual Phage and Yeast Display of Antibodies and Recombinant Proteins
April 29 – 30, 2013
Phage and yeast display are essential tools for engineering the next generation of antibody libraries. The technology is being exploited for half life extension, epitope mapping, membrane targets, blood-brain-barrier entry, and intracellular targets. Ligands for previously intractable targets are being derived through directed evolution for a spectrum of novel constructs, including bispecific antibodies and ADCs, antibody fragments and alternative scaffolds. Deep sequencing of antibody libraries is improving library diversity and yielding drug candidates with improved efficacy. Plan to attend this year's meeting to see how to improve the capacity for drug candidates to be developed, manufactured and scaled-up.
» Click here to learn more about this engineering stream
14th Annual Engineering Antibodies: Challenging Targets, Next Generation Research Methods and Antibody Therapeutics for Autoimmune Diseases
May 1 – 2, 2013
The field of antibody engineering is at an exciting point in its development, with new generations of therapeutic antibodies now reaching the market, great advances in protein science and a body of clinical evidence that can be used to inform the development of safe, highly effective therapies for unmet medical needs. Engineering Antibodies combines groundbreaking discovery stage work in target identification, challenging targets and protein engineering with the application of these foundations to new biotherapeutics.
» Click here for more information on the engineering antibodies stream
4th Annual Engineering Bispecific Antibodies: The Future of Antibody Development
April 29 – May 3, 2013
Bispecific and multiclonal antibodies are one of the most promising and exciting areas of protein engineering. The range of therapeutic uses for bispecific antibodies is expanding beyond oncology to target diseases of the immune system, heart and CNS. This meeting will discover the remaining challenges and creative problem solving that have been used to make successful bispecific formats. The latest solutions for improving efficacy and minimizing toxicity will be explored.
» Click to learn more
Visit http://www.giiconference.com/chi252869-2013/ to learn more about all the programs and streams featured at PEGs 2013
Event Organizers: Need to reach biotech, pharmaceutical, and healthcare executives in Asia?
For over a decade, Global Information Inc, through our GlobalReach event service, has connected conference and event organizers in the West with attendees, exhibitors, and sponsors in the East. Offering affordable fixed-price translation, localization, and conference marketing services, GlobalReach is bridges the gap between cultures to connect organizers with the fastest growing markets on the planet. Visit our website or contact us today to learn more.
About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.
Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Global Information, Inc.